Lanean...
ASCO 2018: highlights in HER2-positive metastatic breast cancer
At the 2018 ASCO Annual Meeting, data from several interesting studies in HER2-positive metastatic breast cancer were presented. While not immediately practice changing, these trials indicate the future directions of drug development in this field. Early phase studies with novel antibody-drug conjug...
Gorde:
| Argitaratua izan da: | Memo |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Springer Vienna
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6280772/ https://ncbi.nlm.nih.gov/pubmed/30595754 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12254-018-0441-x |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|